H5N2减毒活疫苗初免-H5N1灭活疫苗加强接种诱导流感病毒血凝素茎部特异性抗体应答
研究对60名参与者(40人先接种两剂H5N2减毒活疫苗、一年后加强一剂H5N1灭活疫苗;20人仅接种一剂H5N1灭活疫苗)的血清进行ELISA和微量中和试验,检测血凝素茎部反应性抗体。初免组茎部特异性抗体水平显著高于未初免组,加强后第7、28、90天分别有22.5%、70.5%、57.5%的初免者茎部抗体滴度四倍及以上升高,未初免组无升高。初免组茎部抗体GMT峰值显著高于仅接种灭活疫苗组。
要点
- 初免组加强后第7、28、90天分别有22.5%、70.5%、57.5%出现茎部抗体滴度四倍及以上升高,未初免组无升高。
- 初免组茎部抗体GMT峰值24675(95%CI 19531-31174)显著高于仅接种灭活疫苗组8877(95%CI 7140-11035),p<0.0001。
- 初免组茎部抗体中和活性也升高,未初免组未升高。
核心结论
- 初免-加强接种策略可有效诱导血凝素茎部反应性抗体,茎部抗体是开发诱导茎部反应性抗体疫苗的有吸引力的靶点。
研究设计与样本
- 研究使用先前研究采集的60名参与者血清样本,采集时间为接种前及加强接种后第7、28、90天。
- 40名参与者先接种两剂H5N2减毒活疫苗、一年后加强一剂H5N1灭活疫苗,20名参与者仅接种一剂H5N1灭活疫苗。
- 采用酶联免疫吸附试验(ELISA)和微量中和试验检测茎部反应性抗体。
主要发现
- ELISA和微量中和试验均显示初免组茎部特异性抗体水平显著高于未初免组。
- ELISA结果显示加强后第7、28、90天分别有22.5%、70.5%、57.5%的初免参与者茎部抗体滴度四倍及以上升高,未初免组无升高。
- 初免组茎部抗体GMT峰值24675(95%CI 19531-31174)显著高于仅接种灭活疫苗组8877(95%CI 7140-11035),p<0.0001。
- 初免组茎部抗体中和活性也升高,未初免组未升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence and spread of highly pathogenic avian influenza (H5N1) viruses have raised global concerns of a possible human pandemic, spurring efforts towards H5N1 influenza vaccine development and improvements in vaccine administration methods. We previously showed that a prime-boost vaccination strategy induces robust and broadly cross-reactive antibody responses against the hemagglutinin globular head domain. Here, we specifically measure antibodies against the conserved hemagglutinin stem region in serum samples obtained from the prior study to determine whether stalk-reactive antibodies can also be induced by the prime-boost regimen. METHOD: Serum samples collected from 60 participants before vaccination and on days 7, 28 and 90 following boosting vaccination were used in this study. 40 participants received two doses of live attenuated H5N2 vaccine (LAIV H5N2) followed by one dose of inactivated H5N1 vaccine a year later, while 20 participants received only the inactivated H5N1 vaccine. We tested these serum samples for stalk-reactive antibodies via enzyme-linked immunosorbent (ELISA) and microneutralization assays. RESULTS: Stalk-specific antibody levels measured by both assays were found to be significantly higher in primed individuals than the unprimed group. ELISA results showed that 22.5, 70.5 and 57.5% of primed participants had a four-fold or more increase in stalk antibody titers on days 7, 28 and 90 following boosting vaccination, respectively; whereas the unprimed group had no increase. Peak geometric mean titers (GMT) for stalk antibodies in the LAIV H5N2 experienced group (24,675 [95% CI; 19,531-31,174]) were significantly higher than those who received only the inactivated H5N1 vaccine (8877 [7140-11,035]; p < 0·0001). Moreover, stalk antibodies displaying neutralizing activity also increased in primed participants, but not in the unprimed group. CONCLUSION: Our finding emphasizes the importance of prime-boost vaccination for effectively inducing stalk antibodies, which is an attractive target for developing vaccines that induce stalk reactive antibodies.
引用
- Kongchanagul A, Samnuan K, Wirachwong P, et al. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses. Vaccine. 2019. PMID: 31708176. doi:10.1016/j.vaccine.2019.10.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。